Doctor Who Fought 8 Years for Children’s Lives Now Hit with Legal Notice
Hyderabad paediatrician Dr. Sivaranjani Santosh, who advocated for clearer ORS labelling, receives legal notice from companies linked to Kenvue and Johnson & Johnson.
Table of contents [Show]
- ₹10,000 Crore Biopharma Push: What India’s New Budget Strategy Really Means
- What Is Biopharma SHAKTI
- Understanding Biologics and Biosimilars
- Why the Budget Focuses on Biologics
- Strengthening India’s Regulatory Backbone
- Expanding Pharmaceutical Education and Research
- Boosting Clinical Trial Infrastructure
- Industry Response to the Budget
- From Generics to Global Biopharma Leadership
- Implications for Patients and Public Health
- Conclusion: Ambition Backed by Execution Will Decide Outcomes
₹10,000 Crore Biopharma Push: What India’s New Budget Strategy Really Means
In a significant policy announcement, the Union Budget has proposed a ₹10,000 crore outlay over the next five years to strengthen India’s biopharmaceutical sector. The initiative, named Biopharma SHAKTI, is aimed at positioning India as a global hub for advanced medicines, particularly biologics and biosimilars, marking a decisive shift in healthcare and pharmaceutical priorities.
What Is Biopharma SHAKTI
Biopharma SHAKTI is envisioned as an ecosystem-building strategy rather than a standalone funding scheme. The focus is on facilitating domestic production of complex biopharmaceutical products, reducing reliance on imports, and supporting innovation through improved research capacity, skilled manpower, and manufacturing infrastructure.
Understanding Biologics and Biosimilars
Biologics are medicinal products derived from living organisms such as bacteria, yeast, or animal cells, making them fundamentally different from conventional chemical drugs. They are large, structurally complex molecules whose safety and efficacy depend heavily on precise manufacturing processes. Biosimilars are highly similar versions of approved biologic drugs that demonstrate no clinically meaningful differences in safety, purity, or efficacy from the reference product. Due to their complexity, both biologics and biosimilars require advanced manufacturing facilities, stringent regulatory oversight, and extensive clinical evaluation.
Why the Budget Focuses on Biologics
The growing burden of cancer, autoimmune disorders, and chronic non-communicable diseases has increased dependence on biologic therapies worldwide. India has traditionally excelled in generic medicines, but biologics represent a higher-value, technology-intensive segment. By prioritising biologics and biosimilars, the Budget signals a strategic move to transition Indian pharmaceutical manufacturing from volume-driven generics to innovation-driven biopharma products.
Strengthening India’s Regulatory Backbone
A critical component of the Biopharma SHAKTI initiative is the strengthening of the Central Drugs Standard Control Organisation. Regulatory capacity is expected to be enhanced through scientific expertise, faster evaluation pathways, and alignment with global standards, all of which are essential for approving complex biologic and biosimilar products.
The Budget proposes the establishment of three new National Institutes of Pharmaceutical Education and Research, along with the upgrading of existing NIPERs. This expansion is intended to develop a workforce trained specifically in biopharmaceutical sciences, regulatory affairs, and biologics manufacturing, areas that are currently resource-intensive and skill-dependent.
Boosting Clinical Trial Infrastructure
Biologics and biosimilars often require large, well-regulated clinical trials to establish comparability and long-term safety. The Budget’s proposal to develop a nationwide network of over 1,000 accredited clinical trial sites is expected to significantly improve India’s capacity to conduct high-quality trials for complex therapies.
Industry Response to the Budget
Pharmaceutical industry stakeholders have welcomed the Biopharma SHAKTI announcement, describing it as a necessary step for India’s long-term competitiveness. The emphasis on biologics, regulatory reform, and clinical research infrastructure has been viewed as crucial for attracting investment and encouraging innovation beyond conventional generics.
From Generics to Global Biopharma Leadership
India’s pharmaceutical identity has long been tied to affordable generic medicines. The Budget’s biopharma focus reflects an ambition to move up the global value chain by competing in biologics and biosimilars, markets traditionally dominated by a few multinational players.
Implications for Patients and Public Health
Domestic production of biologics and biosimilars has the potential to improve access to advanced therapies while lowering costs. If executed effectively, the initiative could enhance treatment availability for chronic and life-threatening conditions that currently depend heavily on imported biologic drugs.
Conclusion: Ambition Backed by Execution Will Decide Outcomes
The ₹10,000 crore Biopharma SHAKTI push represents a forward-looking investment in India’s healthcare and pharmaceutical future. Its success will ultimately depend on regulatory efficiency, sustained funding, workforce development, and the ability to translate policy announcements into functional systems that support safe, effective, and affordable biopharmaceutical innovation.
